{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2"},{"groupId":"OG001","value":"5.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"276"},{"groupId":"OG001","value":"426"}],"units":"Participants"}],"groups":[{"description":"Ixazomib 3 mg, capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 through 26.","id":"OG000","title":"Placebo"},{"description":"Ixazomib 3 mg, capsule, orally, once on Days 1, 8, and 15 of each 28-day cycle from Cycles 1 to 4 that may have been escalated to 4 mg thereafter up to Cycle 26.","id":"OG001","title":"Ixazomib"}],"paramType":"NUMBER","populationDescription":"Safety Population included all participants who received at least 1 dose of ixazomib or placebo. Three placebo participants who erroneously received a single dose of ixazomib were included in the ixazomib arm of the safety population. The percentages are rounded off to the single nearest decimal point.","reportingStatus":"POSTED","timeFrame":"From randomization until PD or death (up to 52 months)","title":"Percentage of Participants Who Develop a New Primary Malignancy","type":"SECONDARY","unitOfMeasure":"percentage of participants"}